Advanced Melanoma
101
22
33
29
Key Insights
Highlights
Success Rate
74% trial completion
Published Results
24 trials with published results (24%)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
9.9%
10 terminated out of 101 trials
74.4%
-12.2% vs benchmark
7%
7 trials in Phase 3/4
83%
24 of 29 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 29 completed trials
Clinical Trials (101)
Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
Multiple Adjunct Therapies to Improve Immunotherapy Treatment in Patients With Locally Advanced or Metastatic Melanoma or Advanced Hepatocellular Cancer
Memory-Like Natural Killer Cells With Nivolumab and Relatlimab in Advanced or Metastatic Melanoma After Progression on Checkpoint Inhibitors
Au-TMP and Radiotherapy for Advanced Melanoma With Anti-PD-1 Therapy
Optimizing Tumor-Infiltrating Lymphocyte (TIL) Harvest Site and Patient Selection With CD8-PET Imaging in Patients With
Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial
iSCIB1+ in Combination With Ipilimumab and Nivolumab as First-Line Treatment for Advanced Unresectable Melanoma
Intratumoral Injection of LTX-315 in Combination With Pembrolizumab in Advanced Melanoma
A Phase II Trial of LM103 in Advanced Melanoma
ctDNA-guided Addition of Ipilimumab to Patients Receiving Nivolumab and Relatlimab
High-Intensity Exercise and High-Fiber Diet for Immunotherapy Outcomes in Melanoma Patients: The DUO Trial
A Clinical Study of T3011 in Subjects With Advanced Melanoma
MELCHRONO: A Prospective Randomized Study Investigating Chrono-immunotherapy for Advanced Melanoma.
Sitagliptin With Pembro in RCC and Melanoma
VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]
Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1
The Immune Effects of Fermented Wheat Germ Nutritional Supplementation in Patients With Advanced Solid Tumor Cancers Being Treated With Standard of Care Checkpoint Inhibitors
A Trial of Pembrolizumab and Metformin Versus Pembrolizumab Alone in Advanced Melanoma
AB821 in Adult Participants With Locally Advanced or Metastatic Solid Tumors
CMP-001 in Combination With Nivolumab Compared to Nivolumab Monotherapy in Subjects With Advanced Melanoma